• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmacogenetics >NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population.
【24h】

NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population.

机译：NAT2缓慢乙酰化和膀胱癌的风险：对22例在一般人群中进行的病例对照研究的荟萃分析。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The NAT2 gene is involved in phase II detoxification of aromatic monoamines, a class of known bladder carcinogens. Certain allelic combinations result in the slow acetylation phenotype, which is thought to increase bladder cancer risk. We conducted a meta-analysis of all identifiable published case-control studies conducted in the general population that had examined the relationship of acetylation status and bladder cancer risk (22 studies, 2496 cases, 3340 controls). Using meta-analysis techniques that employed weighting based on individual-study variation, slow acetylators had an approximately 40% increase in risk compared with rapid acetylators [odds ratio (OR) 1.4, 95% confidence interval (CI) 1.2-1.6]. Statistical tests indicated, however, that pooling of all studies, or of studies conducted in Caucasian populations, hid potentially important heterogeneity in the individual study results, and suggested that the relationship of NAT2 slow acetylation and bladder cancer risk might differ by geographical region. Studies conducted in Asia generated a summary OR of 2.1 (CI 1.2-3.8), in Europe, a summary OR of 1.4 (CI 1.2-1.6), and in the USA, a summary OR of 0.9 (CI 0.7-1.3). Among European studies, the relationship between NAT2 slow acetylation and bladder cancer risk did not differ by method used to assess acetylation status (older drug-based phenotyping methods: 10 studies, OR 1.5, CI 1.2-1.8; more recent NAT2 genotyping methods: four studies, OR 1.4, CI 1.1-1.7). Our results suggest that in most populations studied to date, NAT2 slow acetylation status is associated with a modest increase in bladder cancer risk.
机译：NAT2基因参与一类已知的膀胱致癌物芳香族单胺的II期解毒。某些等位基因组合会导致缓慢的乙酰化表型，这被认为会增加膀胱癌的风险。我们对在普通人群中进行的所有可识别的已发表病例对照研究进行了荟萃分析，这些研究检查了乙酰化状态与膀胱癌风险之间的关系（22项研究，2496例病例，3340例对照）。使用基于个人研究变异权重的荟萃分析技术，与快速乙酰化药物相比，慢速乙酰化药物的风险增加约40％[比值比（OR）1.4，95％置信区间（CI）1.2-1.6]。然而，统计测试表明，所有研究或在白种人人群中进行的研究的合并，在单个研究结果中均隐藏了潜在的重要异质性，并表明NAT2慢乙酰化与膀胱癌风险的关系可能因地理区域而异。在亚洲进行的研究得出的总OR为2.1（CI 1.2-3.8），在欧洲产生的总OR为1.4（CI 1.2-1.6），而在美国，其总OR为0.9（CI 0.7-1.3）。在欧洲的研究中，NAT2缓慢乙酰化与膀胱癌风险之间的关系在用于评估乙酰化状态的方法上没有差异（较早的基于药物的表型分析方法：10项研究，OR 1.5，CI 1.2-1.8;最新的NAT2基因分型方法：四种研究，或1.4，CI 1.1-1.7）。我们的结果表明，在迄今为止研究的大多数人群中，NAT2缓慢的乙酰化状态与膀胱癌风险的适度增加相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号